TargetBeta
KDR
kinase insert domain receptor · also FLK1, VEGFR, VEGFR2, CD309 · CD molecules
15 programs in company-led studies act on KDR, from 14 companies: 9 in phase 3, 4 approved with new studies. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (15 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| cabozantinibrule | Exelixis | phase 4 | 3610 running | MET | ChEMBL |
| lenvatinibrule | Eisai | phase 4 | 815 running | FLT1, FLT4 | NCIt |
| regorafenibrule | Bayer | phase 4 | 404 running | ABL1, BRAF, DDR2, EPHA2, FGFR1, FGFR2, FLT1, FLT4, FRK, KIT, MAPK11, NTRK1, PDGFRA, PDGFRB, RAF1, RET, TEK | ChEMBL |
| nintedanibrule | Boehringer Ingelheim | phase 4 | 761 running | FGFR1, FGFR2, FGFR3, FGFR4, FLT1, FLT4, PDGFRA, PDGFRB | ChEMBL |
| zanzalintinibrule | Exelixis | phase 3 | 1715 running | AXL, MET | NCIt |
| apatinibrule | Jiangsu HengRui Medicine | phase 3 | 478 running | – | ChEMBL |
| anlotinibrule | Sino Biopharmaceutical | phase 3 | 407 running | FLT4, KIT, PDGFRB | ChEMBL |
| AXL/FLT3/VEGFR2 Inhibitor KC1036rule | Beijing Konruns Pharmaceutical | phase 3 | 76 running | AXL, FLT3 | NCIt |
| Ramucirumabrule | Eli Lilly | phase 3 | 585 running | – | NCIt |
| vorolanibrule | Betta Pharmaceuticals | phase 3 | 245 running | – | the studies' text |
| Axitinibrule | Pfizer | phase 3 | 454 running | FLT1, FLT4 | ChEMBL |
| chiauranibrule | Chipscreen Biosciences | phase 3 | 154 running | AURKB, FLT1, FLT4 | ChEMBL |
| Aurora B/VEGFR/FGFR Inhibitor AL8326rule | Advenchen Laboratories Nanjing | phase 3 | 84 running | – | NCIt |
| cp-547632rule | PanOptica | phase 2 | 61 running | – | ChEMBL |
| Anti-PD-1/Anti-VEGFR2 Bispecific Antibody OTP-01rule | Ottimo Pharma | phase 2 | 11 running | PDCD1 | NCIt |
Also acted on by the same programs
Conditions their studies are in
- Neoplasms, 9 programs
- Carcinoma, Non-Small-Cell Lung, 8 programs
- Carcinoma, Hepatocellular, 5 programs
- Carcinoma, Renal Cell, 5 programs
- Macular Degeneration, 3 programs
- Ovarian Neoplasms, 3 programs
- Small Cell Lung Carcinoma, 3 programs
- Colorectal Neoplasms, 2 programs
- Diabetic Retinopathy, 2 programs
- Sarcoma, 2 programs
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Nov 30, 2026lenvatinib · Eisai · phase 4 · NCT07081633
- Dec 15, 2026zanzalintinib · Exelixis · phase 3 · NCT05678673
- Dec 30, 2026AXL/FLT3/VEGFR2 Inhibitor KC1036 · Beijing Konruns Pharmaceutical · phase 3 · NCT06194734
- Dec 30, 2026cp-547632 · PanOptica · phase 2 · NCT07764965
- Jan 8, 2027Axitinib · Pfizer · phase 3 · NCT06495918
- Feb 28, 2027chiauranib · Chipscreen Biosciences · phase 3 · NCT06492915
- Mar 31, 2027anlotinib · Sino Biopharmaceutical · phase 3 · NCT07438886
- May 2027Ramucirumab · Eli Lilly · phase 3 · NCT05999994
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.